

ALLEGATO A

UNIVERSITÀ DEGLI STUDI DI MILANO

selezione pubblica per n.____ posto/i di Ricercatore a tempo determinato con finanziamento esterno ai sensi dell'art.24, comma 3, lettera a) della Legge 240/2010 per il settore concorsuale 05/E1 - Biochimica Generale, settore scientifico-disciplinare BIO/10 - Biochimica presso il Dipartimento di SCIENZE BIOMEDICHE E CLINICHE "L. SACCO", (avviso bando pubblicato sulla G.U. n. 12 del 14.2.2017) Codice concorso 3501

Luca Mogni CURRICULUM VITAE

INFORMAZIONI PERSONALI (NON INSERIRE INDIRIZZO PRIVATO E TELEFONO FISSO O CELLULARE)

COGNOME	MOLOGNI
NOME	LUCA
DATA DI NASCITA	05-07-1971

PROFESSIONAL EXPERIENCE

2013 – today: GALKEM srl / Spin-Off of the University of Milano-Bicocca

Co-founder, CEO

2004 – today: University of Milano-Bicocca, Monza

Senior Research Fellow

2001 – 2003: National Cancer Institute, Milan

Post-doc

1998 – 2002: University of Helsinki, Helsinki, Finland

PhD Studentship

1998: National Cancer Institute, Milan

Research Fellow

1997: Mario Negri Institute for Pharmacological Research, Milan

Civilian service

1993 – 1996: National Cancer Institute, Milan

Internship for M.Sc. degree and practical training

EDUCATION

2009 – University of Helsinki – PhD degree in Medicine

1997 – University of Milan – Professional License to practice as a Biologist

1996 – University of Milan – M.Sc. degree in Biology

GRANTS, HONORS & AWARDS

- 2015** – Ricerca finalizzata 2013 “Development of selective inhibitors of crizotinib-resistant oncogenic ALK kinase”; role: Partner Unit. 235,000 € / 3 years
- 2015** – Research Grant from European Commission: “ALK Activation as a target of Translational Science (ALKATRAS): Break free from cancer”. H2020 Program; Role: Partner Organisation.
- 2015** – Editorial board member of the *World Journal of Clinical Oncology*
- 2013** – Habilitation as Associate Professor in Molecular Biology (05/E2)
- 2013** – Research Grant from Italian Ministry of Research (MIUR): “Selective inhibitors of oncogenic ALK kinase”; role: Principal Investigator. 453,000 € / 3 years
- 2001** – Research Fellowship “Italian Foundation for Cancer Research (FIRC)” – 3 years
- 1998** – Research Fellowship “Istituto Superiore di Sanità” – 1 year

PUBLICATIONS

Total IF = 294.3

Mean IF = 5.6

Total citations = 2,571

Mean citations = 46

h-index = 25

Contemporary hc-index = 18

ARTICLES (n=56)

1. [The Novel PIM1 Inhibitor NMS-P645 Reverses PIM1-Dependent Effects On TMPRSS2/ERG Positive Prostate Cancer Cells And Shows Anti-Proliferative Activity In Combination With PI3K Inhibition](#)
Mologni L*, Magistroni V*, Casuscelli F, Montemartini M, Gambacorti-Passerini C.
*equal contribution
J Cancer. **2017**, 8(1):140-145. doi:10.7150/jca.15838. IF= 3.3 - Citations: 0
2. [RET kinase inhibitors: a review of recent patents \(2012–2015\)](#)
Mologni L, Gambacorti-Passerini C, Goekjian P, Scapozza L.
Expert Opin Ther Pat. **2017**, 27(1):91-99. IF= 4.3- Citations: 0
3. [Synergistic activity of ALK and mTOR inhibitors for the treatment of NPM-ALK positive lymphoma](#)
Redaelli S, Ceccon M, Antolini L, Rigolio R, Pirola A, Peronaci M, Gambacorti-Passerini C, **Mologni L**.
Oncotarget. **2016** Nov 8;7(45):72886-72897. doi: 10.18632/oncotarget.12128.. IF= 6.3 - Citations: 0

4. [Entrectinib, a Pan-TRK, ROS1 and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications](#)
Ardini E, Menichincheri M, Banfi P, Bosotti R, De Ponti C, Pulci R, Ballinari D, Ciomei M, Texido G, Degrassi A, Avanzi N, Amboldi N, Saccardo MB, Casero D, Orsini P, Bandiera T, **Mologni L**, Anderson D, Wei G, Harris J, Vernier JM, Li G, Felder E, Donati D, Isacchi A, Pesenti E, Magnaghi P, Galvani A.
Mol Cancer Ther, **2016** Mar 3. pii: molcanther.0758.2015. IF= 5.7 - Citations: 6
5. [Excess of NPM-ALK oncogenic signaling promotes cellular apoptosis and drug dependency](#)
Ceccon M, Boggio Merlo ME, **Mologni L**, Poggio T, Varesio LM, Menotti M, Bombelli S, Rigolio R, Manazza AD, Di Giacomo F, Ambrogio C, Giudici G, Casati C, Mastini C, Compagno M, Turner SD, Gambacorti-Passerini C, Chiarle R, Voena C.
Oncogene **2016**, 35: 3854-3865. IF= 8.5 - Citations: 1
6. [Efficacy of a cancer vaccine against ALK-rearranged lung tumors.](#)
Voena C, Menotti M, Mastini C, Di Giacomo F, Longo DL, Castella B, BoggioMerlo ME, Ambrogio C, Wang Q, Minero VG, Poggio T, Martinengo C, D'Amico L, Panizza E, **Mologni L**, Cavallo F, Altruda F, Butaney M, Capelletti M, Inghirami G, Jänne PA, Chiarle R.
Cancer Immunol Res. **2015**, Sep 29. [Epub ahead of print]. IF= 3.9 - Citations: 3
7. [Current and future treatment of anaplastic lymphoma kinase-rearranged cancer.](#)
Mologni L.
World J Clin Oncol. **2015**, 6(5):104-108. EDITORIAL. IF= n.d. - Citations: 0
8. [Activity of second-generation ALK inhibitors against crizotinib resistant mutants in NPM-ALK compared to EML4-ALK model.](#)
Fontana D, Ceccon M, Gambacorti-Passerini C, **Mologni L**.
Cancer Med. **2015**, doi: 10.1002/cam4.413. IF= 2.5 - Citations: 12
9. [NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922.](#)
Mologni L, Ceccon M, Pirola A, Chiriano G, Piazza R, Scapozza L, Gambacorti-Passerini C.
Oncotarget **2015**, 6(8):5720-34. IF= 6.3 - Citations: 10
10. [Treatment Efficacy and Resistance Mechanisms using the Second-generation ALK Inhibitor AP26113 in Human NPM-ALK-positive Anaplastic Large Cell Lymphoma.](#)
Ceccon M, **Mologni L**, Giudici G, Piazza R, Pirola A, Fontana D, Gambacorti-Passerini C.
Mol Cancer Res. **2015**, 13(4):775-83. IF= 4.3 - Citations: 19
11. [Expanding the portfolio of anti-ALK weapons.](#)
Mologni L.
Transl Lung Cancer Res. **2015**, 4(1):5-7. EDITORIAL. IF= n.d. - Citations: 2
12. [Mechanisms of RET signalling in cancer: current and future implications for targeted therapy.](#)
Plaza-Menacho I, **Mologni L**, McDonald NQ.
Cellular Signal. **2014**, 26(8):1743-52. IF= 4.3 - Citations: 21
13. [Synthesis and biological evaluation of benzo\[4,5\]imidazo\[1,2-c\]pyrimidine and benzo\[4,5\]imidazo\[1,2-a\]pyrazine derivatives as anaplastic lymphoma kinase inhibitors.](#)
Tardy S, Orsato A, **Mologni L**, Bisson WH, Donadoni C, Gambacorti-Passerini C, Scapozza L, Gueyrard D, Goekjian PG.
Bioorg Med Chem. **2014**, 22:1303-1312. IF= 2.8 - Citations: 5

14. [Crizotinib in advanced, chemoresistant Anaplastic Lymphoma Kinase-positive lymphoma patients.](#)
 Gambacorti-Passerini C, Farina F, Stasia A, Redaelli S, Ceccon M, **Mologni L**, Messa C, Guerra L, Giudici G, Sala E, Mussolin L, Deeren D, King MH, Steurer M, Ordemann R, Cohen AM, Grube M, Bernard L, Chiriano G, Piazza R.
J Natl Cancer Inst. **2014**, 106(2):djt378. IF= 12.6 - Citations: 46
15. [Ponatinib is a potent inhibitor of wild-type and drug-resistant gatekeeper mutant RET kinase.](#)
Mologni L, Redaelli S, Morandi A, Plaza-Menacho I, Gambacorti-Passerini C.
Mol Cell Endocrinol. **2013**, 377(1-2):1-6. IF= 4.4 - Citations: 24
16. [Epigenetic Silencing of the Proapoptotic Gene BIM in Anaplastic Large Cell Lymphoma through an MeCP2/SIN3a Deacetylating Complex.](#)
 Piazza R, Magistroni V, Mogavero A, Andreoni F, Ambrogio C, Chiarle R, **Mologni L**, Bachmann PS, Lock RB, Collini P, Pelosi G, Gambacorti-Passerini C.
Neoplasia **2013**, May;15(5):511-22. IF= 4.3 - Citations: 18
17. [Crizotinib-resistant NPM-ALK mutants confer differential sensitivity to unrelated ALK inhibitors.](#)
 Ceccon M*, **Mologni L***, Bisson W, Scapozza L, Gambacorti-Passerini C.
 *equal contribution.
Mol Cancer Res. **2013**, 11(2): 122-132. IF= 4.3 - Citations: 32
18. [Recurrent SETBP1 mutations in atypical chronic myeloid leukemia.](#)
 Piazza R, Valletta S, Winkelmann N, Redaelli S, Spinelli R., Pirola A, Antolini L, **Mologni L**, Donadoni C, Papaemmanuil E, Schnittger S, Kim D-W, Boultonwood J, Rossi F, Gaipa G, De Martini GP, Jang H. G, Fantin VR, Bignell G, Magistroni V, Haferlach T, Campbell PJ, Pogliani EM, Cross NCP, Gambacorti-Passerini C.
Nat Genet. **2013**, 45(1):18-27. IF= 29.4 - Citations: 131
19. [Synergistic effects of combined Wnt/KRAS inhibition in colorectal cancer cells.](#)
Mologni L, Brussolo S, Ceccon M, Gambacorti-Passerini C.
PLoS ONE **2012**, 7(12): e51449. IF= 3.2 - Citations: 21
20. [Three novel patients derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors.](#)
 Redaelli S, **Mologni L**, Rostagno R, Piazza R, Magistroni V, Ceccon M, Viltadi M, Flynn D, Gambacorti-Passerini C.
Am J Hematol. **2012**, 87(11):E125-8. doi: 10.1002/ajh.23338. IF= 3.8 - Citations: 29
21. [New developments in the treatment of anaplastic lymphoma kinase-driven malignancies.](#)
Mologni L and Gambacorti-Passerini C.
Clin Invest. **2012**, 2(8):835-852. REVIEW. IF= n.d. Citations: n.d.
22. [Inhibitors of the anaplastic lymphoma kinase.](#)
Mologni L.
Expert Opin Investig Drugs **2012**, 21(7):985-994. REVIEW. IF= 5.5 - Citations: 29
23. [ERG deregulation induces PIM-1 over-expression and aneuploidy in prostate epithelial cells.](#)
 Magistroni V, **Mologni L**, Sanselicio S, Reid J, Redaelli S, Piazza R, Viltadi M, Bovo G, Strada G, Grasso M, Gariboldi M, Gambacorti-Passerini C.
PLoS ONE **2011**, 6(11):e28162. IF= 3.2 - Citations: 16

24. [Dissection of the RET/ \$\beta\$ -catenin interaction in the TPC1 thyroid cancer cell line.](#)
Tartari CJ, Donadoni C, Manieri E, **Mologni L**, Della Mina P, Villa A, Gambacorti-Passerini C.
Am J Cancer Res. **2011**, 1(6):716-725. IF= 4.2 - Citations: 6
25. [Design, Synthesis and Biological Activity of Urea Derivatives as Anaplastic Lymphoma Kinase Inhibitors.](#)
Boije af Gennäs G*, **Mologni L***, Ahmed S*, Rajaratnam M, Marin O, Lindholm N, Viltadi M, Gambacorti-Passerini C, Scapozza L, Yli-Kauhahuoma J.
*equal contribution.
Chem Med Chem. **2011**, 6(9):1680 – 1692. IF= 3.0 - Citations: 12
26. [Development of RET Kinase Inhibitors for Targeted Cancer Therapy.](#)
Mologni L.
Curr Med Chem. **2011**, 18(2):162-75. REVIEW. IF= 3.9 - Citations: 32
27. [FAK binds RET via its FERM domain priming a direct and reciprocal RET-FAK transactivation mechanism.](#)
Plaza-Menacho I, Morandi A, **Mologni L**, Boender P, Gambacorti-Passerini C, Magee AI, Hofstra RMW, Knowles P, McDonald NQ, Isacke CM.
J Biol Chem. **2011**, 286(19):17292-302. IF= 4.6 - Citations: 28
28. [Sphingosine Kinase I overexpression is regulated by signaling through PI3K, AKT2, and mTOR in Imatinib-Resistant Chronic Myeloid Leukemia \(CML\) cells.](#)
Marfe G, Di Stefano C, Gambacorta A, Ottone T, Martini V, Abruzzese E, **Mologni L**, Sinibaldi-Salimei P, de Fabritis P, Gambacorti-Passerini C, Amadori S, Birge RB.
Exp Hematol. **2011**, 39(6):653-665. IF= 2.5 - Citations: 19
29. [Colorectal tumors are effectively eradicated by combined inhibition of \$\beta\$ -Catenin, KRAS, and the oncogenic transcription factor ITF2.](#)
Mologni L*, Dekhil H*, Ceccon M, Purgante S, Lan C, Cleris L, Magistroni V, Formelli F, Gambacorti-Passerini CB.
*equal contribution.
Cancer Res. **2010 Sep 15**, 70(18):7253-63. IF= 9.3 - Citations: 27
30. [Inhibitors of the RET tyrosine kinase based on 2-\(alkylsulfanyl\)-4-\(3-thienyl\)nicotinonitrile scaffold.](#)
Brandt W*, **Mologni L***, Preu L, Lemcke T, Gambacorti-Passerini C, Kunick C.
*equal contribution.
Eur J Med Chem. **2010**, 45(7):2919-27. IF= 3.4 - Citations: 17
31. [Synthesis, structure-activity relationship and crystallographic studies of 3-substituted indolin-2-one RET inhibitors.](#)
Mologni L, Rostagno R, Brussolo S, Knowles PP, Kjaer S, Murray-Rust J, Rosso E, Zambon A, Scapozza L, McDonald NQ, Lucchini V, Gambacorti-Passerini C.
Bioorg Med Chem. **2010**, 18(4):1482-96. IF= 2.8 - Citations: 38
32. [Valproic acid enhances bosutinib cytotoxicity in colon cancer cells.](#)
Mologni L, Cleris L, Magistroni V, Piazza R, Boschelli F, Formelli F, Gambacorti-Passerini C.
Int J Cancer **2009**, 124(8):1990-6. IF= 5.1 - Citations: 17

33. [BRAF silencing by short hairpin RNA or chemical blockade by PLX4032 leads to different responses in melanoma and thyroid carcinoma cells.](#)
Sala E, **Mologni L**, Truffa S, Gaetano C, Bollag GE, Gambacorti-Passerini.
Mol Cancer Res. **2008**, 6(5):1-9. IF= 4.3 - Citations: 126
34. [Characterization of compound 584, an Abl-inhibitor with lasting effects.](#)
Puttini M, Redaelli S, Moretti L, Brussolo S, Gunby RH, **Mologni L**, Marchesi E, Cleris L, Donella-Deana A, Drückes P, Sala E, Lucchini V, Kubbutat M, Formelli F, Zambon A, Scapozza L, Gambacorti-Passerini C.
Haematologica **2008**, 93(5):653-661. IF= 5.8 - Citations: 12
35. [Sorafenib functions to potently suppress RET tyrosine kinase activity by direct enzymatic inhibition and promoting RET lysosomal degradation independent of proteasomal targeting.](#)
Plaza-Menacho I, **Mologni L**, Sala E, Gambacorti-Passerini C, Magee AI, Links TP, Hofstra RMW, Barford D, Isacke CM.
J Biol Chem. **2007**, 282(40):29230-40. IF= 4.6 - Citations: 62
36. [Bcr-Abl stabilizes \$\beta\$ -catenin in Chronic Myeloid Leukemia through its tyrosine phosphorylation.](#)
Coluccia AML, Vacca A, Duñach M, **Mologni L**, Redaelli S, Bustos VH, Benati D, Pinna LA, and Gambacorti Passerini C.
EMBO J. **2007**, 26(5):1456-66. IF= 10.4 - Citations: 122
37. [Oncogenic fusion tyrosine kinases as molecular targets for anti-cancer therapy.](#)
Gunby RH, Tartari C, Sala E, Puttini M, Gambacorti-Passerini C, **Mologni L**.
Anti-Canc Agents Med Chem. **2007**, 7(6):594-616. REVIEW. IF= 2.5 - Citations: 17
38. [Targeted deletion of the muscular dystrophy gene myotilin does not perturb muscle structure or function in mice.](#)
Moza M, **Mologni L**, Trocovic R, Faulkner G, Partanen J, Carpen O.
Mol Cell Biol. **2007**, 27(1):244-252. IF= 4.7 - Citations: 36
39. [Structural insights into the ATP binding pocket of the anaplastic lymphoma kinase by site directed mutagenesis, inhibitor binding analysis and homology modeling.](#)
Gunby RH, Ahmed S, Sottocornola R, Gasser M, Redaelli S, **Mologni L**, Tartari CJ, Belloni V, Gambacorti-Passerini C, Scapozza L.
J Med Chem. **2006**, 49(19):5759-68. IF= 5.4 - Citations: 29
40. [Inhibition of RET tyrosine kinase by SU5416.](#)
Mologni L, Sala E, Cazzaniga S, Rostagno R, Kuoni T, Puttini M, Bain J, Redaelli S, Riva B, Scapozza L, Gambacorti-Passerini C.
J Mol Endocrinol. **2006**, 37 (2): 199-212. IF= 3.1 - Citations: 44
41. [A rapid method for the purification of wild-type and V804M mutant RET catalytic domain: a tool to study thyroid cancer.](#)
Sala E, **Mologni L**, Cazzaniga S, Papinutto E, Gambacorti- Passerini C.
Int J Biol Macromol. **2006**, 39(1-3):60-65. IF= 2.9 - Citations: 1
42. [Unique Substrate Specificity of Anaplastic Lymphoma Kinase \(ALK\): Development of Phosphoacceptor Peptides for the Assay of ALK Activity.](#)
Donella-Deana A, Marin O, Cesaro L, Gunby RH, Ferrarese A, Coluccia AML, Tartari CJ, **Mologni L**, Scapozza L, Gambacorti-Passerini C, Pinna LA.
Biochemistry **2005**, 44(23):8533-8542. IF= 3.0 - Citations: 35

43. [Expression, purification and inhibition of human RET tyrosine kinase.](#)
Mologni L, Sala E, Riva B, Cesaro L, Cazzaniga S, Redaelli S, Marin O, Pasquato N, Donella-Deana A, Gambacorti-Passerini C.
Protein Expr Purif. **2005**, 41(1):177-185. IF= 1.7 - Citations: 25
44. [Characterization of mouse myotilin and its promoter.](#)
Mologni L, Moza M, Lalowski MM, Carpén O.
Biochem Biophys Res Commun. **2005**, 329(3):1001-1009. IF= 2.3 - Citations: 17
45. [PNAs as novel cancer therapeutics.](#)
Mologni L and Gambacorti-Passerini C.
Int J Pept Res Ther. **2003** (formerly: *Lett Pept Sci*), 10(3-4):297-308. REVIEW. IF= 0.9 - Citations: 1
46. [Inhibition of PML/RAR \$\alpha\$ and PML expression in acute promyelocytic leukemia cells by anti-PML Peptide Nucleic Acid \(PNA\).](#)
Mologni L, Marchesi E, Nielsen PE, Gambacorti-Passerini C.
Cancer Res. **2001**, 61: 5468-5473. IF= 9.3 - Citations: 54
47. [Developmental expression of myotilin, a gene mutated in limb-girdle muscular dystrophy type 1A.](#)
Mologni L, Salmikangas P, Fougerousse F, Beckmann JS, Carpén O.
Mech Dev. **2001** ;103(1-2):121-5. IF= 2.4 - Citations: 12
48. [Retinoid-dependent growth inhibition, differentiation and apoptosis in acute promyelocytic leukemia cells. Expression and activation of caspases.](#)
 Gianni M, Ponzanelli I, **Mologni L**, Reichert U, Rambaldi A, Terao M, Garattini E.
Cell Death Differ. **2000** ;7(5):447-60. IF= 8.2 - Citations: 75
49. [Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification.](#)
 le Coutre P, Tassi E, Varella-Garcia M, Barni R, **Mologni L**, Cabrita G, Marchesi E, Supino R, Gambacorti-Passerini C.
Blood **2000** ;95(5):1758-66. IF= 10.5 - Citations: 442
50. [In vitro transcriptional and translational block of the bcl-2 gene operated by peptide nucleic acid.](#)
Mologni L, Nielsen PE, Gambacorti-Passerini C.
Biochem Biophys Res Commun. **1999** ;264(2):537-43. IF= 2.3 - Citations: 49
51. [In vivo eradication of human BCR/ABL-positive leukemia cells with an ABL kinase inhibitor.](#)
 le Coutre P, **Mologni L**, Cleris L, Marchesi E, Buchdunger E, Giardini R, Formelli F, Gambacorti-Passerini C.
J Natl Cancer Inst. **1999** ;91(2):163-8. IF= 12.6 - Citations: 306
52. [The novel synthetic retinoid 6-\[3-adamantyl-4-hydroxyphenyl\]-2-naphthalene carboxylic acid \(CD437\) causes apoptosis in acute promyelocytic leukemia cells through rapid activation of caspases.](#)
Mologni L, Ponzanelli I, Bresciani F, Sardiello G, Bergamaschi D, Gianni M, Reichert U, Rambaldi A, Terao M, Garattini E.
Blood **1999** ;93(3):1045-61. IF= 10.5 - Citations: 88

53. [Cross-talk between retinoic acid and interferons: molecular mechanisms of interaction in acute promyelocytic leukemia cells.](#)
Garattini E, **Mologni L**, Ponzanelli I, Terao M.
Leuk Lymphoma **1998** ;30(5-6):467-75. REVIEW. IF= 2.9 -. Citations: 15
54. [Additive antisense effects of different PNAs on the in vitro translation of the PML/RARalpha gene.](#)
Mologni L, le Coutre P, Nielsen PE, Gambacorti-Passerini C.
Nucleic Acids Res. **1998** ;26(8):1934-8. IF= 9.1 - Citations: 47
55. [Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL+ leukemic cells and induces apoptosis.](#)
Gambacorti-Passerini C, le Coutre P, **Mologni L**, Fanelli M, Bertazzoli C, Marchesi E, Di Nicola M, Biondi A, Corneo GM, Belotti D, Pogliani E, Lydon NB.
Blood Cells Mol Dis. **1997**, 23(3):380-94. IF= 2.6 - Citations: 269
56. [In vitro transcription and translation inhibition by anti-promyelocytic leukemia \(PML\)/retinoic acid receptor alpha and anti-PML peptide nucleic acid.](#)
Gambacorti-Passerini C, **Mologni L**, Bertazzoli C, le Coutre P, Marchesi E, Grignani F, Nielsen PE.
Blood **1996**, 88(4):1411-7. IF= 10.5 - Citations: 66

EDITED BOOKS

1. [The myopathic protein myotilin in developing mouse and in muscle function.](#)
Mologni L. Doctoral Thesis. University of Helsinki, Faculty of Medicine. *Yliopistopaino, Helsinki*, **2009**. ISBN 978-952-10-5733-5 (paperback); ISBN 978-952-10-5734-2 (PDF); <http://urn.fi/URN:ISBN:978-952-10-5734-2>
2. [PNAs as novel cancer therapeutics.](#)
Mologni L and Gambacorti-Passerini C.; in “*Peptide Nucleic Acids, Morpholinos and Related Antisense Biomolecules*” ed. by During M. and Janson C. Landes Series: Medical Intelligence Unit, *Landes Bioscience/Eurekah.com*, **2006**. ISBN 0-306-48230-4

PATENTS

1. Gambacorti-Passerini C, Mologni L, Scapozza L, Bisson W, Goekjian PG, D'Attoma J. (**WO2015001024**) **2-acylaminothiazoles for the treatment of cancer.**
2. Gambacorti-Passerini C, Joseph B, Mologni L, Scapozza L, Bisson W, Ahmed S, Goekjian PG, Tardy S, Orsato A, Gueyrard D. (**WO2013167730**) **Alpha-carbolines for the treatment of cancer.**
3. Gambacorti-Passerini C, Mologni L, Scapozza L, Ahmed S, Goekjian PG, Garcia P, Gueyrard D, Joseph B, Popowycz F, Schneider C. (**WO2010025872**) **α -carboline inhibitors of NPM-ALK, Ret and Bcr-Abl.**
4. Gambacorti-Passerini C, Mologni L. (**WO2009108755**) **Pharmaceutical combinations for the treatment of cancer.**

5. Pinna L, Donella-Deana A, Marin O, Mologni L, Gunby R, Gambacorti-Passerini C, Scapozza L. ([WO2004079326](#)) **Anaplastic lymphoma kinase assay, reagents and composition thereof.**

TECHNICAL SKILLS

- All major **cell biology** techniques (subculturing, FACS, proliferation, apoptosis, colony assays, transfection, infection, cell cloning, immunohistochemistry, immunofluorescence, etc.)
- All major **molecular biology** techniques (DNA cloning, nucleic acids extraction, Western, Southern, Northern blotting, PCR, qPCR, IP, in situ hybridization, siRNA, CRISPR/Cas9, etc.)
- **Biochemistry**/Medicinal chemistry (ELISA, kinase assay, other enzymatic assays, molecular modelling, SAR, ATP competition assay, etc.)
- Recombinant **protein expression** (bacterial cells, insect cells, cell-free TnT) and **purification** (FPLC, batch; affinity, ion exchange, size-exclusion chromatography)
- **Mouse** models (targeting vector construction, ES clones screening, genotyping, xenograft models, oral gavage, organ dissection, embryos dissection, tissue fixation)

SOFTWARE

- Microsoft Office (Word, Excel, PowerPoint)
- GraphPad Prism
- Photoshop
- Chromas, DNASTAR, Vector NTI, Integrative Genomics Viewer (IGV)
- ChemDraw, ChemSketch, ISIS/Base, ISIS/Draw
- SYBYL, 3D-Mol viewer

PEER-REVIEW

Reviewer for the following Journals:

- *Cancer Research*
- *Oncotarget*
- *Molecular Cancer Therapeutics*
- *Expert Opinion On Investigational Drugs*
- *Molecular Cancer*
- *British Journal of Cancer*
- *International Journal of Molecular Science*
- *BMC Cancer*
- *Journal of Molecular Endocrinology*
- *Expert Review of Haematology*
- *General Physiology and Biophysics*
- *Letters in Drug Design and Discovery*
- *Apoptosis*
- *Clinical Gastroenterology and Hepatology*
- *Molecules*
- *Biotechnology and Applied Biochemistry*
- *Pharmacogenomics and Personalized Medicine*

TEACHING

Classes and exams:

- **Molecular mechanisms of diseases / Therapeutic applications of biotechnology**
Medical Biotechnology M.Sc. program - University of Milan-Bicocca

Classes/Seminars:

- **Molecular biology of colorectal cancer**
Oncology Specialty School - University of Milan-Bicocca
- **Biology and therapy of muscular dystrophies**
Childhood Neuro and Psychomotricity - B.Sc. program - University of Milan-Bicocca

Supervision of students:

➤ **PhD:**

1. Geeta Sharma. *Single-cell RNA sequencing for the detection of drug-resistant lymphoma in ALCL patients*. University of Milan-Bicocca. PhD DIMET program. 2016-2019
2. Praveen Khandelwal. *Elucidating the oncogenic role of early genetic events in chronic myeloid leukemia*. University of Milan-Bicocca. PhD program in Experimental Haematology 2012-2015.
3. Monica Ceccon. *Identification and analysis of NPM-ALK kinase domain mutations conferring resistance to crizotinib*. University of Milan-Bicocca. PhD program in Experimental Haematology 2009-2012.
4. Stefania Purgante. *Validation of molecular targets in melanoma*. University of Milan-Bicocca. PhD program in Experimental Haematology 2009-2011.
5. Elisa Sala. *Analysis and inhibition of RET- and BRAF-dependent oncogenic signalling in thyroid neoplasia*. The Open University. 2005-2008.

➤ **M.Sc.:**

1. Francesca Mangia. *Structure-function studies of Caulobacter crescentus ShkA, a c-di-GMP activated histidine kinase*. University of Basel/University of Milano-Bicocca – Year 2016-2017.
2. Marion Nigoghossian. *Overcoming drug resistance in ALK-positive tumors*. University of Lyon UCBL1 – Year 2016.
3. Mariantonia Costanza. *Identification and functional characterization of concomitant BCORL1 and BRAF V600E p47-ΔN mutations in melanoma cells resistant to vemurafenib*. University of Milano-Bicocca – Year 2015-2016.
4. Diletta Fontana. *Activity of clinical ALK inhibitors across a panel of crizotinib-resistant ALK mutants derived from non-small-cell lung cancer: an in vitro study on BaF/F3 NPM-ALK model*. University of Milano-Bicocca – Year 2012-2013.
5. Stefania Purgante. *Characterization of therapeutic targets in solid cancer*. University of Milano-Bicocca – Year 2008-2009.
6. Stefano Sanselicio. *Validation of TMPRSS2-ERG oncogene as a therapeutic target in prostate carcinoma cells*. University of Milano-Bicocca – Year 2007-2008.
7. Sara Cazzaniga. *Screening of selective inhibitors of oncogenic tyrosine kinase RET*. University of Milan – Faculty of Sciences – Year 2004-2005
8. Elisa Sala. *Expression, purification and characterization of RET catalytic domain*. University of Milan – Faculty of Pharmacy – Year 2002-2003

9. Sara Redaelli. *Expression and purification of ABL catalytic domain Abl and its use in Bcr-Abl inhibitors screening*. University of Milan – Faculty of Pharmacy – Year 2002-2003

➤ **B.Sc.:**

1. Valentina Bertola – 2008 – University of Milano-Bicocca – Biotechnology.
2. Stefano Sanselicio – 2006 – University of Milano-Bicocca – Biotechnology.
3. Francesca Nova – 2005 – University of Milano-Bicocca – Biotechnology.

OTHER

Foreign languages: English, fluent; Finnish, elementary.

Sports: free climbing, hiking, skiing, football, tennis, swimming, floorball, skating, canoeing, rafting.

I hereby grant permission to use my personal data in accordance with the Italian Leg. Dec. 196/2003

Monza, 10 March 2017